Trial
NCT03502577
BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Fred Hutchinson Cancer Center
Collaborators
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; The Leukemia and Lymphoma Society
Condition
Recurrent Plasma Cell Myeloma
Intervention
BCMA-specific CAR-expressing T Lymphocytes
Why stopped
Closed per SRC Low Accrual Policy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-01-08